Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: Results of the Institut Gustave-Roussy phase II trial

H. Assi, G. Missenard, P. Terrier, C. le Pechoux, S. Bonvalot, D. Vanel, J. B. Meric, T. Tursz, A. LeCesne

Research output: Contribution to journalArticle

Abstract

Purpose: To improve outcomes in localized osteosarcoma and to reduce the duration of preoperative chemotherapy, we conducted a phase ii trial assessing the efficacy of an intensive protracted regimen without methotrexate (API-AI-REGIMEN) in adolescent and adult patients with newly diagnosed disease. Patients and Methods: Induction chemotherapy consisted of 2 cycles (4 courses) of doxorubicin 60 mg/m2 (days 1 and 15), cisplatin 100 mg/m2 (day 1), and ifosfamide 5 g/m2 (days 2 and 15). The primary endpoint was good histologic response [GHR (≤5% identifiable tumour cells)]. Results: From March 1993 to March 2000, 32 patients [median age: 21 years (range: 15-49 years)] were administered 126 induction courses. The median time between chemotherapy courses was 15 days (range: 12-32 days). All but 3 patients underwent conservative surgery. Toxicity was mainly hematologic, with febrile neutropenia occurring in 35% of patients and grades 3-4 thrombocytopenia in 35%. The GHR rate was 47%. The median follow-up was 64 months (range: 30-115 months). The 5-year event-free and overall survivals were 65% [95% confidence interval (ci): 48%-79%] and 69% (95% ci: 50%-83%) respectively. Two secondary hematologic malignancies occurred: 1 acute myelocytic leukemia (M5) in a poor responder with concomitant relapse, and 1 myelodysplastic syndrome in a patient achieving GHR. Conclusions: Despite hematologic toxicity, the results observed with the API-AI-REGIMEN compare favourably with those observed during previous induction chemotherapy containing methotrexate in adult patients and the pediatric population treated at our institution. These promising results have to be validated by an ongoing national multicentre trial coordinated by the French Sarcoma Group.

Original languageEnglish
Pages (from-to)23-31
Number of pages9
JournalCurrent Oncology
Volume17
Issue number6
Publication statusPublished - 2010

Fingerprint

Induction Chemotherapy
Osteosarcoma
Methotrexate
Confidence Intervals
Drug Therapy
Febrile Neutropenia
Ifosfamide
Myelodysplastic Syndromes
Hematologic Neoplasms
Acute Myeloid Leukemia
Sarcoma
Doxorubicin
Cisplatin
Multicenter Studies
Disease-Free Survival
Pediatrics
Recurrence
Population

Keywords

  • Induction chemotherapy
  • Osteosarcoma

ASJC Scopus subject areas

  • Oncology

Cite this

Assi, H., Missenard, G., Terrier, P., le Pechoux, C., Bonvalot, S., Vanel, D., ... LeCesne, A. (2010). Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: Results of the Institut Gustave-Roussy phase II trial. Current Oncology, 17(6), 23-31.

Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma : Results of the Institut Gustave-Roussy phase II trial. / Assi, H.; Missenard, G.; Terrier, P.; le Pechoux, C.; Bonvalot, S.; Vanel, D.; Meric, J. B.; Tursz, T.; LeCesne, A.

In: Current Oncology, Vol. 17, No. 6, 2010, p. 23-31.

Research output: Contribution to journalArticle

Assi, H, Missenard, G, Terrier, P, le Pechoux, C, Bonvalot, S, Vanel, D, Meric, JB, Tursz, T & LeCesne, A 2010, 'Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: Results of the Institut Gustave-Roussy phase II trial', Current Oncology, vol. 17, no. 6, pp. 23-31.
Assi, H. ; Missenard, G. ; Terrier, P. ; le Pechoux, C. ; Bonvalot, S. ; Vanel, D. ; Meric, J. B. ; Tursz, T. ; LeCesne, A. / Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma : Results of the Institut Gustave-Roussy phase II trial. In: Current Oncology. 2010 ; Vol. 17, No. 6. pp. 23-31.
@article{596faa41b8b340a6905ae1843d6b42a0,
title = "Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: Results of the Institut Gustave-Roussy phase II trial",
abstract = "Purpose: To improve outcomes in localized osteosarcoma and to reduce the duration of preoperative chemotherapy, we conducted a phase ii trial assessing the efficacy of an intensive protracted regimen without methotrexate (API-AI-REGIMEN) in adolescent and adult patients with newly diagnosed disease. Patients and Methods: Induction chemotherapy consisted of 2 cycles (4 courses) of doxorubicin 60 mg/m2 (days 1 and 15), cisplatin 100 mg/m2 (day 1), and ifosfamide 5 g/m2 (days 2 and 15). The primary endpoint was good histologic response [GHR (≤5{\%} identifiable tumour cells)]. Results: From March 1993 to March 2000, 32 patients [median age: 21 years (range: 15-49 years)] were administered 126 induction courses. The median time between chemotherapy courses was 15 days (range: 12-32 days). All but 3 patients underwent conservative surgery. Toxicity was mainly hematologic, with febrile neutropenia occurring in 35{\%} of patients and grades 3-4 thrombocytopenia in 35{\%}. The GHR rate was 47{\%}. The median follow-up was 64 months (range: 30-115 months). The 5-year event-free and overall survivals were 65{\%} [95{\%} confidence interval (ci): 48{\%}-79{\%}] and 69{\%} (95{\%} ci: 50{\%}-83{\%}) respectively. Two secondary hematologic malignancies occurred: 1 acute myelocytic leukemia (M5) in a poor responder with concomitant relapse, and 1 myelodysplastic syndrome in a patient achieving GHR. Conclusions: Despite hematologic toxicity, the results observed with the API-AI-REGIMEN compare favourably with those observed during previous induction chemotherapy containing methotrexate in adult patients and the pediatric population treated at our institution. These promising results have to be validated by an ongoing national multicentre trial coordinated by the French Sarcoma Group.",
keywords = "Induction chemotherapy, Osteosarcoma",
author = "H. Assi and G. Missenard and P. Terrier and {le Pechoux}, C. and S. Bonvalot and D. Vanel and Meric, {J. B.} and T. Tursz and A. LeCesne",
year = "2010",
language = "English",
volume = "17",
pages = "23--31",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "6",

}

TY - JOUR

T1 - Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma

T2 - Results of the Institut Gustave-Roussy phase II trial

AU - Assi, H.

AU - Missenard, G.

AU - Terrier, P.

AU - le Pechoux, C.

AU - Bonvalot, S.

AU - Vanel, D.

AU - Meric, J. B.

AU - Tursz, T.

AU - LeCesne, A.

PY - 2010

Y1 - 2010

N2 - Purpose: To improve outcomes in localized osteosarcoma and to reduce the duration of preoperative chemotherapy, we conducted a phase ii trial assessing the efficacy of an intensive protracted regimen without methotrexate (API-AI-REGIMEN) in adolescent and adult patients with newly diagnosed disease. Patients and Methods: Induction chemotherapy consisted of 2 cycles (4 courses) of doxorubicin 60 mg/m2 (days 1 and 15), cisplatin 100 mg/m2 (day 1), and ifosfamide 5 g/m2 (days 2 and 15). The primary endpoint was good histologic response [GHR (≤5% identifiable tumour cells)]. Results: From March 1993 to March 2000, 32 patients [median age: 21 years (range: 15-49 years)] were administered 126 induction courses. The median time between chemotherapy courses was 15 days (range: 12-32 days). All but 3 patients underwent conservative surgery. Toxicity was mainly hematologic, with febrile neutropenia occurring in 35% of patients and grades 3-4 thrombocytopenia in 35%. The GHR rate was 47%. The median follow-up was 64 months (range: 30-115 months). The 5-year event-free and overall survivals were 65% [95% confidence interval (ci): 48%-79%] and 69% (95% ci: 50%-83%) respectively. Two secondary hematologic malignancies occurred: 1 acute myelocytic leukemia (M5) in a poor responder with concomitant relapse, and 1 myelodysplastic syndrome in a patient achieving GHR. Conclusions: Despite hematologic toxicity, the results observed with the API-AI-REGIMEN compare favourably with those observed during previous induction chemotherapy containing methotrexate in adult patients and the pediatric population treated at our institution. These promising results have to be validated by an ongoing national multicentre trial coordinated by the French Sarcoma Group.

AB - Purpose: To improve outcomes in localized osteosarcoma and to reduce the duration of preoperative chemotherapy, we conducted a phase ii trial assessing the efficacy of an intensive protracted regimen without methotrexate (API-AI-REGIMEN) in adolescent and adult patients with newly diagnosed disease. Patients and Methods: Induction chemotherapy consisted of 2 cycles (4 courses) of doxorubicin 60 mg/m2 (days 1 and 15), cisplatin 100 mg/m2 (day 1), and ifosfamide 5 g/m2 (days 2 and 15). The primary endpoint was good histologic response [GHR (≤5% identifiable tumour cells)]. Results: From March 1993 to March 2000, 32 patients [median age: 21 years (range: 15-49 years)] were administered 126 induction courses. The median time between chemotherapy courses was 15 days (range: 12-32 days). All but 3 patients underwent conservative surgery. Toxicity was mainly hematologic, with febrile neutropenia occurring in 35% of patients and grades 3-4 thrombocytopenia in 35%. The GHR rate was 47%. The median follow-up was 64 months (range: 30-115 months). The 5-year event-free and overall survivals were 65% [95% confidence interval (ci): 48%-79%] and 69% (95% ci: 50%-83%) respectively. Two secondary hematologic malignancies occurred: 1 acute myelocytic leukemia (M5) in a poor responder with concomitant relapse, and 1 myelodysplastic syndrome in a patient achieving GHR. Conclusions: Despite hematologic toxicity, the results observed with the API-AI-REGIMEN compare favourably with those observed during previous induction chemotherapy containing methotrexate in adult patients and the pediatric population treated at our institution. These promising results have to be validated by an ongoing national multicentre trial coordinated by the French Sarcoma Group.

KW - Induction chemotherapy

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=78650144360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650144360&partnerID=8YFLogxK

M3 - Article

C2 - 21151406

AN - SCOPUS:78650144360

VL - 17

SP - 23

EP - 31

JO - Current Oncology

JF - Current Oncology

SN - 1198-0052

IS - 6

ER -